Trial Profile
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Crisantaspase; Crisantaspase; Cytarabine; Cytarabine; Daunorubicin; Dexrazoxane; Etoposide; Filgrastim; Fludarabine; Idarubicin; Mitoxantrone; Sorafenib
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 31 Oct 2022 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
- 31 Oct 2022 Planned primary completion date changed from 1 Jun 2026 to 1 Jun 2025.
- 31 Oct 2022 Status changed from recruiting to active, no longer recruiting.